Analyst: It looks difficult for Exiqon
According to a sector analyst, gene analysis company Exiqon finds itself in difficult times and there is no light at the end of the tunnel this year, as the company will struggle to meet its full-year guidance.
BY BENJAMIN WERNER CHRISTENSEN
Things really have to pick up in the second part of the year, for the listed, Danish gene analysis company to live up to its full-year revenue guidance of approximately DKK 135 million. That guidance was even downgraded in connection with the publication of the company’s interim statement.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Exiqon CEO: Extremely disappointing adjustment
For abonnenter
“I think they have done a great job”
For abonnenter
Exiqon CEO: Not completely satisfied
For abonnenter
